Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.

about

Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.

Item

http://www.wikidata.org/entity/Q47329066

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Investigational PD-1 inhibitor ...... ctors of response and outcome.

@en

Investigational PD-1 inhibitor ...... ctors of response and outcome.

@nl

type

Item

label

Investigational PD-1 inhibitor ...... ctors of response and outcome.

@en

Investigational PD-1 inhibitor ...... ctors of response and outcome.

@nl

prefLabel

Investigational PD-1 inhibitor ...... ctors of response and outcome.

@en

Investigational PD-1 inhibitor ...... ctors of response and outcome.

@nl

P1476

Investigational PD-1 inhibitor ...... ctors of response and outcome.

@en

P2093

Andres Chang

http://www.w3.org/2001/XMLSchema#string

Christopher R Flowers

http://www.w3.org/2001/XMLSchema#string

Danielle Schlafer

http://www.w3.org/2001/XMLSchema#string

Pamela B Allen

http://www.w3.org/2001/XMLSchema#string

P2860

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Viral immune evasion due to persistence of activated T cells without effector function

T cell activation

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Molecular and cellular insights into T cell exhaustion

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

P304

55-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/13543784.2018.1416091

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29228840

http://www.w3.org/2001/XMLSchema#string

P932

5762391

http://www.w3.org/2001/XMLSchema#string